Neubond

Cover Block

PUBLIC

Field	Value
Name	Neubond
Tagline	Advanced wearable technology for recovering mobility after stroke and neuro-injury
Headquarters	London, United Kingdom
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology Type	Hardware (wearable medical device)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2): Patrick Sagastegui Alva, Jumpei Kashiwakura
Funding Label	Pre-seed
Total Disclosed	$250,000 grant round [Leads on Trees]

Links

PUBLIC

• Website: https://neubond.co.uk/
• LinkedIn: https://uk.linkedin.com/company/neubond
• Crunchbase: https://www.crunchbase.com/organization/neubond

Executive Summary

PUBLIC

Neubond is an Imperial College London spinout building wearable hardware aimed at helping stroke and neuro-injury survivors rebuild motor function at home, a category where clinician shortages and an ageing population are widening the gap between need and access [Imperial College London] [LinkedIn]. The company was co-founded by Patrick Sagastegui Alva, who completed a PhD in Bioengineering at Imperial College London with published work on wearable haptic devices for proprioceptive encoding, and Jumpei Kashiwakura, previously a Senior Engineer at Toyota Motor Corporation [LinkedIn] [Crunchbase] [Archive ouverte HAL]. The team initially worked on prosthetics before pivoting to stroke rehabilitation, with the current product positioned as a home therapy device that visualises muscle engagement and provides physical feedback to reinforce nerve-to-muscle signalling [Neubond] [Russell Group]. Neubond has disclosed a $250,000 grant round and lists Horizon Europe as a non-dilutive backer, with accelerator support from Innovate UK ICURe and Imperial Venture Catalyst, and won the Health & Wellbeing track at Imperial's 2024 Venture Catalyst Challenge [Leads on Trees] [Imperial College London]. The business model is consumer-oriented (B2C) but, like most home medtech, the realistic path to revenue runs through clinical evidence, regulatory clearance, and reimbursement intermediaries. Over the next 12 to 18 months, the read-throughs that matter are the launch of a monitoring-only first version (a deliberate de-risking step), progress toward clinical trials and regulatory submission, and whether the company converts grant capital into a priced equity round with a named institutional lead [Imperial College London] [NIHR Imperial Biomedical Research Centre].

Data Accuracy: GREEN -- Confirmed by Imperial College London, Crunchbase, LinkedIn, and Leads on Trees.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech / Neurorehabilitation
Technology Type	Hardware (wearable)
Geography	Western Europe (UK)
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed, $250,000 disclosed grant

Company Overview

PUBLIC

Neubond is a London-based Imperial College spinout that began as a prosthetics-focused research effort and reoriented toward stroke rehabilitation after the founders concluded the addressable need and clinical pathway were stronger in neurorehab. According to the company's own framing, Neubond "was born from a shared passion for using technology to impact healthcare in revolutionary ways" and started "with advancements in prosthetics" before applying the same neural-interface and feedback work to stroke recovery [Neubond]. CTO and co-founder Jumpei Kashiwakura has publicly described the pivot in talks at Imperial's HybridNeuro Summer School, framing it as a search for product-market fit [LinkedIn].

The company's milestones to date are largely academic and grant-driven rather than commercial. Neubond was a finalist and category winner in the Health & Wellbeing track of Imperial's 2024 Venture Catalyst Challenge [Imperial College London], received support through the Innovate UK ICURe programme and Imperial Venture Catalyst, and disclosed a $250,000 grant round in 2024 covering early product development and pre-clinical work [Leads on Trees]. The NIHR Imperial Biomedical Research Centre has reported that the company is "currently fundraising to support clinical trials and seek regulatory approval for its home therapy device" [NIHR Imperial Biomedical Research Centre]. A precise incorporation date is not publicly available in the cited sources.

Data Accuracy: GREEN -- Confirmed by Imperial College London, Neubond, and Leads on Trees.

Product and Technology

MIXED

Neubond's product is a wearable device intended for at-home stroke rehabilitation, designed to be worn during daily activities rather than confined to clinic-based therapy sessions [PUBLIC]. Crunchbase describes the system as one that "creates wearable devices for stroke mobility rehabilitation, offering autonomous assistance and therapy during daily activities" [Crunchbase] [PUBLIC]. According to the Russell Group write-up of the Imperial spinout, the home therapy device "helps reinforce the connection between nerves and muscles by providing a physical feedback," which is consistent with the founders' published research on haptic encoding of proprioception [Russell Group] [Archive ouverte HAL] [PUBLIC].

A notable detail in the Imperial College London coverage is the regulatory sequencing: the company plans to first release a version that "monitors movement intention and guides rehabilitation by helping patients visualise which muscles they are using" before introducing an actuating or assistive variant [Imperial College London] [PUBLIC]. That ordering is a deliberate risk-management choice, since a monitoring-and-feedback device generally faces a lighter regulatory pathway than an active therapeutic device. It also lets Neubond gather usage and outcomes data ahead of a more involved submission.

The technical foundations draw directly on Patrick Sagastegui Alva's bioengineering research at Imperial, including co-authored work on a wearable multichannel haptic device for encoding proprioception in the upper limb [Archive ouverte HAL] [PUBLIC]. The depth of the underlying tech stack (sensors, embedded firmware, mobile application layer) is not disclosed in cited public sources [PUBLIC], and no engineering job postings were surfaced that would allow inference about the production stack.

Data Accuracy: GREEN -- Confirmed by Imperial College London, Russell Group, Crunchbase, and Archive ouverte HAL.

Market Research and Opportunity

PUBLIC

Stroke rehabilitation sits at the intersection of two structural pressures that the cited research keeps surfacing: a growing elderly population and a shortage of rehabilitation clinicians, both of which limit how much one-to-one therapy any given survivor actually receives [LinkedIn]. Neubond's own positioning leans on this gap: the company states that "with a growing elderly population and shortages in rehabilitation clinicians, accessibility to care remains a critical issue" [LinkedIn].

Precise TAM, SAM, and SOM figures from named third-party reports are not present in the captured sources for Neubond's specific category, so this report does not assign sizing numbers it cannot attribute. What the cited evidence does establish qualitatively is the demand side. Imperial College London's coverage frames the device as targeting stroke survivors who currently rely on intermittent clinic visits, and quotes patient reaction including "It's given me hope" in the GMA News write-up of an early demonstration [Imperial College London] [GMA News Online]. NIHR's Biomedical Research Centre, a credible clinical translation host, has independently profiled the technology as offering "new hope for stroke survivors seeking to regain mobility" [NIHR Imperial Biomedical Research Centre].

Adjacent and substitute markets matter for how a product like Neubond's gets adopted. The most direct substitutes are conventional in-clinic physiotherapy, tele-rehabilitation video platforms, and functional electrical stimulation (FES) devices already on the market for stroke survivors. Adjacent categories include consumer wearables repurposed for rehabilitation tracking and exoskeleton-style assistive hardware. The regulatory environment in the United Kingdom and European Union is a defining force: a monitoring-only device sits in a different conformity class than an active therapeutic, and Neubond's stated decision to release the monitoring version first is a direct response to this gradient [Imperial College London].

Macro tailwinds the cited sources support include the ageing demographic curve in Western Europe, NHS interest in shifting rehabilitation out of acute settings, and the broader translational push from Russell Group universities to spin out medical hardware [Russell Group]. The headwind is the same one every home medtech company faces: clinical evidence and reimbursement decisions move on multi-year timelines that rarely match a venture-backed cash runway.

Demand signal	Source
Growing elderly population and clinician shortages cited as the access gap Neubond targets	[LinkedIn]
NIHR Imperial BRC profile validating the clinical relevance of the device	[NIHR Imperial Biomedical Research Centre]
Imperial College London coverage of patient response to the prototype	[Imperial College London] [GMA News Online]

The table summarises the qualitative demand signals visible in cited sources; none of them substitute for a sized market figure, but together they suggest a real clinical pull rather than a purely technology-push thesis.

Data Accuracy: YELLOW -- Demand-side qualitative signals are well-cited, but no sized TAM/SAM figures are available from named third-party reports in the captured material.

Competitive Landscape

MIXED

No direct competitors are named in the structured facts captured for Neubond, so this section is written as prose and treats the competitive set by category rather than by named comparator [PUBLIC].

The stroke neurorehabilitation hardware category is populated by three loose clusters. The first is functional electrical stimulation (FES) devices, which actively stimulate muscles and have established clinical evidence and, in some geographies, reimbursement pathways. The second is robotic and exoskeleton-style assistive hardware, typically clinic-deployed and capital-intensive, used during supervised therapy. The third, and the cluster Neubond most directly inhabits, is at-home wearable systems that combine sensing, feedback, and software-guided therapy designed to be used outside the clinic. Tele-rehabilitation software platforms (camera and app-based) sit adjacent and compete for the same clinician attention and patient time, even though they do not contact the body [PUBLIC].

Neubond's defensible edge today, on the cited evidence, rests on three pillars. The first is academic provenance: the company is an Imperial College London spinout with founders whose published research directly underpins the device's haptic feedback approach [Archive ouverte HAL] [Russell Group] [PUBLIC]. The second is non-dilutive validation: support from Innovate UK ICURe, Imperial Venture Catalyst, Horizon Europe, and the NIHR Imperial Biomedical Research Centre is the kind of stack that opens doors to NHS clinical sites [NIHR Imperial Biomedical Research Centre] [Imperial College London] [PUBLIC]. The third is the regulatory sequencing already discussed: starting with a monitoring-only version is a faster route to first market presence than launching an active therapeutic [Imperial College London] [PUBLIC]. These edges are real but perishable. Academic provenance does not block a better-funded entrant, and grant-stack credibility erodes once peers raise priced equity rounds and out-hire the team.

The most exposed flank is capital. Established FES players and well-funded rehab-robotics companies can sustain multi-year clinical trials and reimbursement campaigns that a $250,000 pre-seed cannot [Leads on Trees] [PUBLIC]. The other exposure is channel: stroke rehabilitation purchasing decisions in the UK and EU run through clinicians, hospital trusts, and insurers far more than through direct consumer demand, so a B2C label on the business model is, in practice, likely to require a B2B2C motion that Neubond has not yet publicly built [PRIVATE]. The most plausible 18-month competitive scenario is bifurcated: Neubond becomes a winner if it converts NIHR clinical relationships into a published outcomes study and a priced seed round led by a healthtech-specialist fund; it becomes a loser if a larger FES or rehab-software incumbent launches a comparable home-monitoring product first and absorbs clinician mindshare before Neubond's evidence base lands.

Data Accuracy: YELLOW -- Category structure is well understood, but no named competitors are present in captured sources.

Opportunity

PUBLIC

If Neubond executes against its current plan, the prize is a defensible position as a clinically validated, at-home neurorehabilitation wearable in a market where the structural mismatch between stroke survivor numbers and clinician capacity keeps widening [LinkedIn].

The headline opportunity. The single largest plausible outcome for Neubond is to become a default at-home rehabilitation device prescribed alongside discharge from acute stroke care, first in the United Kingdom through NHS pathways and then across European systems with comparable rehabilitation models. The cited evidence makes this reachable rather than aspirational on three counts: the company is already embedded in the NIHR Imperial Biomedical Research Centre ecosystem, which is a translational pathway specifically designed to move devices from bench to clinic [NIHR Imperial Biomedical Research Centre]; the founders' own research underpins the feedback mechanism, reducing technical execution risk [Archive ouverte HAL]; and the staged regulatory plan (monitoring first, then active therapy) reduces the chance that a single regulatory setback ends the company [Imperial College London].

Growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
NHS Pathway Anchor	Monitoring device cleared and adopted in two to four NHS stroke rehabilitation pathways, generating outcomes data	Published clinical study via NIHR Imperial BRC and a named NHS trust pilot	NIHR BRC affiliation already in place [NIHR Imperial Biomedical Research Centre]
EU Translational Expansion	Horizon Europe support converted into multi-country pilots and CE-marked launch across selected EU markets	Horizon Europe milestone delivery and CE submission for the monitoring variant	Horizon Europe is a confirmed backer [Leads on Trees]; Imperial spinout status supports cross-border credibility [Russell Group]
Strategic Acquisition	Acquired by an established rehabilitation hardware or medical device company seeking a home-care wearable line	A larger incumbent moves to add at-home monitoring to its stroke portfolio after Neubond's first clinical evidence	Stroke rehab consolidation is consistent with the broader medical-device M&A pattern; Neubond's IP and clinical relationships are the kind of asset such buyers acquire [Russell Group]

Each scenario depends on Neubond converting its current grant-funded pre-clinical posture into either priced equity capital or a strategic partnership; the company has publicly stated it is fundraising to support clinical trials and regulatory approval [NIHR Imperial Biomedical Research Centre].

What compounding looks like. The flywheel for a device like Neubond's is data and clinical credibility, not classical network effects. Each NHS or EU pilot generates outcomes data, which strengthens the next regulatory submission and the next reimbursement conversation, which in turn makes the device easier to deploy in the next site. The compounding asset is published evidence, not user count. The cited NIHR Imperial BRC affiliation is the first observable input to that flywheel [NIHR Imperial Biomedical Research Centre], and the founders' existing peer-reviewed work on wearable haptic encoding is the prior credibility the flywheel builds on [Archive ouverte HAL].

The size of the win. A credible sized comparable from the cited sources is not available, so this report does not assign a market-cap figure to any scenario. What can be said with citation is that Neubond's category sits inside Russell Group-supported translational medtech, which has produced acquisition-track and IPO-track outcomes for prior spinouts in adjacent device classes [Russell Group]. If the NHS Pathway Anchor scenario plays out and is followed by EU expansion, Neubond's plausible outcome is a strategically valuable medical device franchise rather than a consumer-scale platform (scenario, not a forecast).

Data Accuracy: YELLOW -- Scenarios are grounded in cited affiliations and confirmed funding; sized outcome figures are deliberately omitted because no named third-party comparable was captured.

Sources

PUBLIC

1. [Neubond] Neubond: Revolutionising Neuro-Rehabilitation | https://neubond.co.uk/

2. [Neubond] Neubond: Our Mission and Vision | https://neubond.co.uk/about-neubond-technology

3. [Imperial College London] Wearable device for restoring movement aims to deliver hope to stroke patients | https://www.imperial.ac.uk/news/267033/wearable-device-restoring-movement-aims-deliver/

4. [Imperial College London] Innovators of the future to compete in Venture Catalyst Challenge final | https://www.imperial.ac.uk/news/252553/innovators-future-compete-venture-catalyst-challenge/

5. [LinkedIn] neubond company page | https://uk.linkedin.com/company/neubond

6. [LinkedIn] Jumpei Kashiwakura profile | https://www.linkedin.com/in/jumpei-kashiwakura/

7. [LinkedIn] Patrick Sagastegui Alva profile | https://www.linkedin.com/in/psagastegui/

8. [Crunchbase] Neubond company profile | https://www.crunchbase.com/organization/neubond

9. [Crunchbase] Neubond tech details | https://www.crunchbase.com/organization/neubond/tech_details

10. [Crunchbase] Jumpei Kashiwakura person profile | https://www.crunchbase.com/person/jumpei-kashiwakura

11. [Leads on Trees] Pioneering Personalized Rehabilitation: Neubond Secures $250,000 Funding in Grant Round for Stroke Patient Devices | https://www.leadsontrees.com/news/pioneering-personalized-rehabilitation-neubond-secures-250,000-funding-in-grant-round-for-stroke-patient-devices

12. [Mirage News] Wearable Device Brings Hope to Stroke Patients | https://www.miragenews.com/wearable-device-brings-hope-to-stroke-patients-1510254/

13. [GMA News Online] It's given me hope: Stroke patient amazed by new rehab device | https://www.gmanetwork.com/news/scitech/technology/923097/it-s-given-me-hope-stroke-patient-amazed-by-new-rehab-device/story/

14. [NIHR Imperial Biomedical Research Centre] Wearable Tech Offers New Hope for Stroke Survivors Seeking to Regain Mobility | https://imperialbrc.nihr.ac.uk/2025/08/15/11208/

15. [Russell Group] Imperial spinout develops new stroke rehabilitation technology | https://www.russellgroup.ac.uk/impact/imperial-spinout-develops-new-stroke-rehabilitation-technology